The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Open accessAbstract
The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds. Pioneering works on HER2-positive breast cancer in the 90s' launched a new era in clinical research and oncology practice that has reshaped the natural history of this disease. In diagnostic pathology the HER2 status is routinely assessed by using a combination of immunohistochemistry (IHC, to evaluate HER2 protein expression levels) and in situ hybridization (ISH, to assess HER2 gene status). For this purpose, international recommendations have been developed by a consensus of experts in the field, which have changed over the years according to new experimental and clinical data. In this review article we will document the changes that have contributed to a better evaluation of the HER2 status in clinical practice, furthermore we will discuss HER2 heterogeneity defined by IHC and ISH as well as by transcriptomic analysis and we will critically describe the complexity of HER2 equivocal results. Finally, we will introduce the clinical impact of HER2 mutations and we will define the upcoming category of HER2-low breast cancer with respect to emerging clinical data on the efficacy of specific anti-HER2 agents in subgroups of breast carcinomas lacking the classical oncogene addition dictated by HER2 amplification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Krop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724
Diéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, I. E., Blackwell, K., Hoersch, S., Xu, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30312-1 · Cited by 667
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Gao, Q., Liang, W.-W., Foltz, S. M., Mutharasu, G., Jayasinghe, R. G., Cao, S., Liao, W.-W., Reynolds, S. M., Wyczalkowski, M. A., Yao, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.050 · Cited by 604
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Krop, I. E., Kim, S.-B., Martin, A. G., LoRusso, P. M., Ferrero, J.-M., Badovinac-Crnjevic, T., Hoersch, S., Smitt, M., & Wildiers, H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30313-3 · Cited by 531
Inferring tumor progression from genomic heterogeneity
Navin, N., Krasnitz, A., Rodgers, L., Cook, K., Meth, J., Kendall, J., Riggs, M., Eberling, Y., Troge, J., Grubor, V., et al. (2010) · Genome Research · doi:10.1101/gr.099622.109 · Cited by 524
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz189 · Cited by 512
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Carey, L. A., Berry, D. A., Cirrincione, C. T., Barry, W. T., Pitcher, B. N., Harris, L. N., Ollila, D. W., Krop, I. E., Henry, N. L., Weckstein, D. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1268 · Cited by 421
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Llombart-Cussac, A., Cortés, J., Paré, L., Galván, P., Bermejo, B., Martínez, N., Vidal, M., Pernas, S., López, R., Muñoz, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30021-9 · Cited by 344
Seol, H., Lee, H. J., Choi, Y., Lee, H. E., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., & Park, S. Y. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.36 · Cited by 330
Hanna, W. M., Rüschoff, J., Bilous, M., Coudry, R. A., Dowsett, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.103 · Cited by 281
Schulz, D., Zanotelli, V. R. T., Fischer, J. R., Schapiro, D., Engler, S., Lun, X.-K., Jackson, H. W., & Bodenmiller, B. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.001 · Cited by 280
Loibl, S., von Minckwitz, G., Schneeweiss, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. M., Sinn, P., Khandan, F., Eidtmann, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7876 · Cited by 258
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., Persons, D. L., Tubbs, R. R., & Hammond, M. E. H. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.611 · Cited by 239
Prat, A., Carey, L. A., Adamo, B., Vidal, M., Tabernero, J., Cortés, J., Parker, J. S., Perou, C. M., & Baselga, J. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju152 · Cited by 233
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S., Persky, N. S., Marini, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 230
Marchiò, C., Lambros, M. B., Gugliotta, P., Di Cantogno, L. V., Botta, C., Pasini, B., Tan, D. S., Mackay, A., Fenwick, K., Tamber, N., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2574 · Cited by 202
Self-citationPrat, A., Pascual, T., De Angelis, C., Gutierrez, C., Llombart-Cussac, A., Wang, T., Cortés, J., Rexer, B., Paré, L., Forero, A., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz042 · Cited by 175
HER2 and Breast Cancer — A Phenomenal Success Story
Hayes, D. F. (2019) · New England Journal of Medicine · doi:10.1056/nejmcibr1909386 · Cited by 163
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
Arriola, E., Marchiò, C., Tan, D. S. P., Drury, S., Lambros, M. B. K., Natrajan, R., Rodríguez-Pinilla, S. M., Mackay, A. G., Tamber, N., Fenwick, K., et al. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.19 · Cited by 151
Self-citationA whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Ferrari, A., Vincent-Salomon, A., Pivot, X., Sertier, A.-S., Thomas, E., Tonon, L., Boyault, S., Mulugeta, E., Treilleux, I., MacGrogan, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms12222 · Cited by 150
Yeh, I., Martin, M. A., Robetorye, R. S., Bolla, A. R., McCaskill, C., Shah, R., Gorre, M. E., Mohammed, M. S., & Gunn, S. R. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.78 · Cited by 144
Press, M. F., Sauter, G., Buyse, M. E., Fourmanoir, H., Quinaux, E., Tsao-Wei, D. D., EIERMANN, W., Robert, N. J., Pieńkowski, T., Crown, J. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6693 · Cited by 142
Lee, H. J., Seo, A. N., Kim, E. J., Jang, M. H., Suh, K. J., Ryu, H. S., Kim, Y. J., Kim, J. H., Im, S., Gong, G., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpirl4guvgk3yx · Cited by 137
Ng, C. K. Y., Martelotto, L. G., Gauthier, A., Wen, H., Piscuoglio, S., Lim, R. S., Cowell, C. F., Wilkerson, P. M., Wai, P. T., Rodrigues, D. N., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0657-6 · Cited by 136
Xu, X., Angelis, C. D., Burke, K. A., Nardone, A., Hu, H., Qin, L., Veeraraghavan, J., Sethunath, V., Heiser, L. M., Wang, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2191 · Cited by 130
Baehner, F. L., Achacoso, N. S., Maddala, T., Shak, S., Quesenberry, C. P., Goldstein, L. C., Gown, A. M., & Habel, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8211 · Cited by 128
Rossi, V., Sarotto, I., Maggiorotto, F., Berchialla, P., Kubatzki, F., Cont, N. T., Redana, S., Martinello, R., Valabrega, G., Aglietta, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0194 · Cited by 123
Collins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. P. (2019) · Cancers · doi:10.3390/cancers11060737 · Cited by 119
Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
Eggemann, H., Ignatov, T., Burger, E., Kantelhardt, E. J., Fettke, F., Thomssen, C., Costa, S. D., & Ignatov, A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0335 · Cited by 117
Neumeister, V. M., Anagnostou, V., Siddiqui, S., England, A. M., Zarrella, E., Vassilakopoulou, M., Parisi, F., Kluger, Y., Hicks, D. G., & Rimm, D. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs438 · Cited by 115
Ou, S. I., Schrock, A. B., Bocharov, E. V., Klempner, S. J., Haddad, C. K., Steinecker, G., Johnson, M. L., Gitlitz, B. J., Chung, J., Campregher, P. V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2224 · Cited by 106
HeterogeneousHER2Gene Amplification
Bartlett, A. I., Starcyznski, J., Robson, T., MacLellan, A., Campbell, F., van de Velde, C. J. �., Hasenburg, A., Markopoulos, C. J., Seynaeve, C., Rea, D. W., et al. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp0en6aqmwetzz · Cited by 104
Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R. J., Lanman, R. B., Berger, M. F., Hyman, D. M., Solit, D. B., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1431 · Cited by 104
Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors
Rye, I. H., Trinh, A. C., Sætersdal, A. B., Nebdal, D. J. H., Lingjærde, O. C., Almendro, V., Polyák, K., Børresen‐Dale, A., Helland, Å., Markowetz, F. M., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12375 · Cited by 103
Allison, K. H., Dintzis, S. M., & Schmidt, R. A. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpxtzskbrip07w · Cited by 101
Sapino, A., Goia, M., Recupero, D., & Marchiò, C. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00129 · Cited by 100
Self-citationOnsum, M. D., Geretti, E., Paragas, V. B., Kudla, A. J., Moulis, S., Luus, L., Wickham, T. J., McDonagh, C. F., MacBeath, G., & Hendriks, B. S. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.015 · Cited by 98
Hou, Y., Nitta, H., Wei, L., Banks, P. M., Portier, B. P., Parwani, A. V., & Li, Z. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4453-8 · Cited by 91
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Elster, N., Collins, D. M., Toomey, S., Crown, J. P., Eustace, A. J., & Hennessy, B. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3250-x · Cited by 90
Ross, J. S., Gay, L. M., Wang, K., Ali, S. M., Chumsri, S., Elvin, J. A., Bose, R., Vergilio, J., Suh, J. H., Yelensky, R., et al. (2016) · Cancer · doi:10.1002/cncr.30102 · Cited by 86
Petrelli, F., Tomasello, G., Barni, S., Lonati, V., Passalacqua, R., & Ghidini, M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4419-x · Cited by 85
Metzger, O., Viale, G., Trippa, L., Li, T., Yardley, D. A., Mayer, I., Abramson, V. G., Arteaga, C. L., Spring, L. M., Waks, A. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.502 · Cited by 80
Zuo, W., Jiang, Y., Wang, Y.-J., Xu, X., Hu, X. Y., Liu, G., Wu, J., Di, G., Yu, K., & Shao, Z.-M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3036 · Cited by 76
The genomic profile of HER2‐amplified breast cancers: the influence of ER status
Marchiò, C., Natrajan, R., Shiu, K., Lambros, M., Rodriguez‐Pinilla, S., Tan, D., Lord, C. J., Hungermann, D., Fenwick, K., Tamber, N., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2423 · Cited by 75
Self-citationChang, M. C., Malowany, J. I., Mazurkiewicz, J., & Wood, M. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.206 · Cited by 74
Wang, Z., Portier, B. P., Gruver, A. M., Bui, S., Wang, H., Su, N. Y., Vo, H.-T., Ma, X.-J., Luo, Y., Budd, G. T., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.10.003 · Cited by 70
Lee, H. J., Kim, J. Y., Park, S. Y., Park, I. A., Song, I. H., Yu, J. H., Ahn, J., & Gong, G. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp51hcgpopwscy · Cited by 69
Perez, E. A., de Haas, S. L., EIERMANN, W., Barrios, C. H., Toi, M., Im, Y., Conte, P., Martín, M., Pieńkowski, T., Pivot, X. B., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5687-0 · Cited by 69
Zhao, S., Liu, X., Jin, X., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y. (2019) · Theranostics · doi:10.7150/thno.35730 · Cited by 67
HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
Wang, T., Xu, Y., Sheng, S., Yuan, H., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., et al. (2017) · Cancer Science · doi:10.1111/cas.13182 · Cited by 66
Hendriks, B. S., Klinz, S. G., Reynolds, J. G., Espelin, C. W., Gaddy, D. F., & Wickham, T. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0180 · Cited by 64
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
Wong, D. J. L., & Hurvitz, S. A. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.08.13 · Cited by 56
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas
Deniziaut, G., Tille, J. C., Bidard, F., Vacher, S., Schnitzler, A., Chemlali, W., Trémoulet, L., Fuhrmann, L., Cottu, P. H., Rouzier, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11819 · Cited by 51
Zhu, Y., Lü, D., Lira, M. E., Xu, Q., Du, Y., Xiong, J., Mao, M., Chung, H. C., & Zheng, G. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.11.027 · Cited by 49
Kurozumi, S., Padilla, M., Kurosumi, M., Matsumoto, H., Inoue, K., Horiguchi, J., Takeyoshi, I., Oyama, T., Ranger‐Moore, J., Allred, D. C., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3856-2 · Cited by 49
Rosa-Rosa, J. M., Caniego-Casas, T., Leskelä, S., Cristóbal, E., González-Martínez, S., Moreno-Moreno, E., López-Miranda, E., Holgado, E., Perez‐Mies, B., Garrido, P., et al. (2019) · Cancers · doi:10.3390/cancers11010074 · Cited by 49
Varga, Z., Tubbs, R. R., Wang, Z., Sun, Y., Noske, A., Kradolfer, D., Bosshard, G., Jochum, W., Moch, H., & Öhlschlegel, C. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1642-8 · Cited by 46
Sapino, A., Maletta, F., di Cantogno, L. V., Macrì, L., Botta, C., Gugliotta, P., Scalzo, M. S., Annaratone, L., Balmativola, D., Pietribiasi, F., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0195 · Cited by 44
Self-citationImpact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer
Xu, B., Shen, J., Guo, W., Zhao, W., Zhuang, Y., & Wang, L. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.035 · Cited by 44
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.
Ménard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M., Gloghini, A., Scalone, S., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn369 · Cited by 35
Self-citationMechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
Kong, X., Zhang, K., Wang, X., Yang, X. C., Li, Y., Zhai, J., Xing, Z., Qi, Y., Gao, R., Feng, X., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194137 · Cited by 35
The Dilemma of HER2 Double-equivocal Breast Carcinomas
Marchiò, C., Dell’Orto, P., Annaratone, L., Geyer, F. C., Venesio, T., Berrino, E., di Cantogno, L. V., Garofoli, A., Rangel, N., Casorzo, L., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001100 · Cited by 32
Self-citationAnnaratone, L., Simonetti, M., Wernersson, E., Marchiò, C., Garnerone, S., Scalzo, M. S., Bienko, M., Chiarle, R., Sapino, A., & Crosetto, N. (2017) · Oncotarget · doi:10.18632/oncotarget.15727 · Cited by 31
Self-citationShafi, H., Astvatsaturyan, K., Chung, F., Mirocha, J., Schmidt, M., & Bose, S. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201403 · Cited by 30
Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L. N. W., Wang, A., Eisenberg, M. T., Rowland, C. M., Hessling, J. J., et al. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080070 · Cited by 24
Intratumoral heterogeneity impacts the response to anti-neu antibody therapy
Song, H., Kim, T. O., Ma, S. Y., Park, J., Choi, J.-H., Kim, J., Kang, M. S., Bae, S. K., Kim, K. H., Kim, T. H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-647 · Cited by 23
Ragazzi, M., Bisagni, A., Gasparini, E., Kuhn, E., Bassano, C., Tamagnini, I., Foroni, M., Bortesi, M., Falco, G., Ferrari, G., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.05.001 · Cited by 16
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features
Ding, Q., Chen, H., Lim, B., Damodaran, S., Chen, W., Tripathy, D., Piha-Paul, S. A., Luthra, R., Meric‐Bernstam, F., & Şahin, A. A. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.07.006 · Cited by 14
Annaratone, L., Sarotto, I., & Marchiò, C. (2018) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_4710-1 · Cited by 7
Self-citation
Cited by
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez-Sáez, O., Adamo, B., Vidal, M., Barnadas, E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00208-2 · Cited by 670
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13112824 · Cited by 267
Trastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Metadata
- Authors
- Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 72
- Pages
- 123-135
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W3006813318
- Cited by
- 377
- References
- 89
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.